Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML

Secondary Acute Myeloid Leukemia Clinical Trial

Official title:

Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of Secondary Acute Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05513131
• Other study ID #: 2022-SR-376
• Status: Recruiting
• Phase: Phase 2
• Start date: September 30, 2021
• Est. completion date: September 30, 2025

Study information

• Verified date: August 2022
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: Huang Fei, MD
• Phone: +8615950523133
• Email: 1533793080[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research is being done to assess the therapeutic efficacy and safety of a promising regimen (Venetoclax combined with Azacitidine and Harringtonine) in patients with secondary AML

This study involves the following:

Venetoclax combined with Azacitidine and Harringtonine

Description:

This is an open-label,single center, clinical trial to evaluate the efficacy and safety of Venetoclax in combination with Azacitidine and Harringtonine in patients with sAML

The FDA has approved the combination therapy of Venetoclax and Decitabine/Azacitidine for elderly (> 60-year-old) patients with newly diagnosed AML not eligible for intensive chemotherapy. Venetoclax is an inhibitor of BCL-2 (B-cell lymphoma 2, a protein that initiates tumor growth, disease progression, and drug resistance), which can lead to cancer cell death.

Homoharringtonine (HHT), a plant alkaloid with antitumor properties originally identified nearly 40 years ago, has a unique mechanism of action by preventing the initial elongation step of protein synthesis. HHT has been used widely in China for the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

Participants will receive 1-2 cycles of intensive treatment and followed with consolidated therapy with the same regimen of 4-6 cycles.If CR is not achieved by induction therapy, re-induction therapy can be continued, and those who have not achieved CR after re-induction therapy will withdraw from the study. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) if the patient meets the criteria for transplantation during treatment and a suitable donor exists After completion of study treatment, participants are followed up every 3 months for up to 2 years.

It is expected that about 30 people will take part in this research study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 30, 2025
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 1) Patients with acute myeloid leukemia (AML) newly diagnosed by bone marrow morphology and immunophenotyping (in line with the WHO 2016 diagnostic criteria), and meet any of the following conditions:

• Patients with treatment-related AML (tAML);

• AML patients with a previous history of MDS or CMML;

• AML patients with myelodysplasia-related cytogenetic abnormalities; 2) Age = 18 years old, and age < 80 years old; 3) Eastern Cooperative Oncology Group (ECOG) performance status score =2; 4) Aspartate aminotransferase (ALT), alanine aminotransferase (AST) and alkaline phosphatase (ALP) = 3 × upper limit of normal (ULN), serum bilirubin = 1.5 × ULN; serum creatinine = 2.0 × ULN; Serum myocardial enzyme <2.0×ULN; 5) LVEF determined by echocardiography =50%; Obtain informed consent signed by the patient or legal representative.

Exclusion Criteria:

• 1) AML with central nervous system (CNS) infiltration; 2) Acute promyelocytic leukemia confirmed by bone marrow morphology or immunophenotyping; 3) Have received Venetoclax treatment in the past; 4) Those who are known to be allergic to any drugs or other ingredients in the program; 5) Currently suffering from active autoimmune disease or a history of autoimmune disease potentially involving the CNS; 6) Known human immunodeficiency virus (HIV) infection; 7) Known history of active hepatitis B or C (HBV, HCV) infection; 8) Pregnant women and women who are trying to conceive; 9) Suffering from severe and/or uncontrolled mental illness; 10) Any life-threatening disease, health condition, or organ system dysfunction that the investigator believes may compromise the safety of the subject, or create an undue risk to the research results; 11) Received major surgery within 4 weeks before randomization; Participate in other clinical investigators at the same time one month before enrollment

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Neoplasm Metastasis
• Secondary Acute Myeloid Leukemia

Intervention

Drug:
• Venetoclax;Azacitidine;Homoharringtonine
A cycle every 28 days Treatment with Venetoclax 100mg d1,200mg d2,400mg d3~d14; Azacitidine 75mg/m2/d,d1~d7 Homoharringtonine 2mg/d d1~d7

Locations

Country	Name	City	State
China	The First Affiliated Hospital with Nanjing Medical University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi)	CR is defined as absolute neutrophil count > 10^9/ L, platelets > 100×10^9/L, red cell transfusion independence, and bone marrow with < 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of < 10^9/L or platelets < 100×10^9/L.	From randomization to the end of Cycle 1 (each cycle is 28 days)
Secondary	Partial Remission (PR) Rate Secondary Outcome Measures: Secondary Outcome Measures: Partial Remission (PR) Rate	PR is defined as bone marrow with 5%~25% blasts, at least 50% lower than the initial diagnosis.	From randomization to the end of Cycle 1 (each cycle is 28 days)
Secondary	Overall Response Rate (ORR)	Complete Remission/ Complete Remission with incomplete count recovery/ Partial Remission/ Morphologic Leukemia Free State	From randomization to the end of Cycle 1 (each cycle is 28 days)
Secondary	Rate of Minimal Residual Disease (MRD) negativity	Percentage of participants who converted to MRD < 10^-3 before initiation of consolidation therapy. MRD is measured by MFC and RT-qPCR.	From randomization to the end of Cycle 1 (each cycle is 28 days)
Secondary	Overall survival (OS)	It is measured from the date of randomization to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.	From the time of randomization to time for up to 2 years
Secondary	Disease-Free Survival (DFS)	It is defined as the time from the date of CR/CRi to the date of recurrence or death.	From the time of randomization to time for up to 2 years
Secondary	The proportion of allogeneic hematopoietic stem cell transplantation	Proportion of allogeneic hematopoietic stem cell transplantation after disease remission	From the time of randomization to time for up to 2 years
Secondary	Cumulative incidence of relapse (CIR)	It is measured from the date of CR/CRi to the date of relapse.	From the time of CR/CRi to time for up to 2 years